Skip to main content
The British Journal of Surgery logoLink to The British Journal of Surgery
. 1986 Apr 1;73(4):278–281. doi: 10.1002/bjs.1800730411

Familial medullary thyroid carcinoma without associated endocrinopathies: A distinct clinical entity

J R Farndon 1,, G S Leightt 2, W G Dilley 3, S B Baylin 4, R C Smallridge 5, T S Harrison 6, S A Wells Jr 7
PMCID: PMC11431776  PMID: 3697657

Abstract

In an evaluation of 213 patients from 15 kindreds with familial medullary thyroid carcinoma (MTC), we detected 41 subjects from two kindreds (L and O) who had MTC but no extra-thyroidal manifestations (hyperparathyroidism, phaeochromocytomas or mucosal neuromas) of multiple endocrine neoplasia (MEN) type 11a or 11b. In screening 178 members of the L and O kindreds, we found no evidence that any of them had died from MTC. To assess whether the malignancy was relatively indolent in these families, 20 selected subjects from the two kindreds were compared with 33 MEN IIa subjects. Both groups had clinically occult disease which was diagnosed biochemically by documenting elevated plasma calcitonin (CT) levels following stimulation with intravenous calcium and pentagastrin. There were no differences in the peak stimulated plasma CT levels at the time of diagnosis (1055 ± 236 pg/ml versus 1096 ± 191 pg/ml) or the incidence of regional lymph node metastases (0/20 versus 1/33) in the two groups. The mean age at diagnosis, however, was significantly higher in patients of the L and O kindreds than in patients with MEN 11a (43·1 ± 3·4 years versus 21·1 ± 2·2 years; P < 0·001) indicating that in the two kindreds the MTC either developed at a later age or grew more slowly. This study demonstrates that MTC may occur in a familial pattern distinct from its presentation as MEN IIa or MEN IIb. In this setting it appears to be the least aggressive form of MTC yet described.

Keywords: Thyroid cancers, familial medullary thyroid carcinoma, multiple endocrine neoplasia

Contributor Information

J R Farndon, University of Newcastle upon Tyne, UK.

G S Leightt, The Duke University Medical Center, Durham, North Carolina, USA.

W G Dilley, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.

S B Baylin, The Oncology Center and Department of Medicine, The Johns Hopkins University Medical Institutions, Washington, DC, USA.

R C Smallridge, The Walter Reed Army Medical Center, Washington, DC, USA.

T S Harrison, The Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.

S A Wells, Jr, University of Newcastle upon Tyne, UK.

References

  • 1. Hazard  JB, Hawk  WA, Crile  GJr. Medullary (solid) carcinoma of the thyroid - a clinicopathologic entity. J Clin Endocr  1959; 19: 152. [DOI] [PubMed] [Google Scholar]
  • 2. Block  MA, Horn  RC, Miller  JM, Barrett  JM, Brush  BE. Medullary carcinoma of the thyroid. Ann Surg  1967; 166: 403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Jackson  CE, Tashjian  AHJr, Block  MA. Detection of medullary thyroid cancer by calcitonin assay in families. Ann Int Med  1973; 78: 845. [DOI] [PubMed] [Google Scholar]
  • 4. Block  MA, Jackson  CE, Greenwald  KA, Yott  JB, Tashjian  AHJr. Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Arch Surg  1980; 115: 142. [DOI] [PubMed] [Google Scholar]
  • 5. Wells  SAJr, Baylin  SB, Gann  DS, Farrell  RE, Dilley  WG, Preissig  SH, Linehan  WM, Cooper  CW. Medullary thyroid carcinoma: relationship of method of diagnosis to pathologic staging. Ann Surg  1978; 188: 377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Wells  SAJr, Baylin  SB, Linehan  WM, Farrell  RE, Cox  EB, Cooper  CW. Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann Surg  1978; 188: 139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Hennessey  JF, Wells  SAJr, Ontjes  DA, Cooper  CW. A comparison of pentagastrin injection and calcium infusion as provocative agents for the detection of medullary carcinoma of the thyroid. J Clin Endocrin Metab  1974; 39: 487. [DOI] [PubMed] [Google Scholar]
  • 8. Baylin  SB, Hsu  TH, Stevens  SA, Kallman  CH, Trump  DL, Beavan  MA. The effects of L-dopa on in vitro and in vivo calcitonin release from medullary thyroid carcinoma. J Clin Endo Metab  1979; 48: 408. [DOI] [PubMed] [Google Scholar]
  • 9. Wells  SAJr, Farndon  JR, Dale  JK, Leight  GS, Dilley  WG. Long-term evaluation of patients with primary parathyroid hyperplasia managed by total parathyroidectomy and heterotopic autotransplantation. Ann Surg  1980; 192: 451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Cohen  G, Goldenberg  M. The simultaneous fluorimetric determination of adrenaline and non-adrenaline in plasma. J Neurochem  1957; 2: 58. [DOI] [PubMed] [Google Scholar]
  • 11. Pisano  JJ, Crout  JR, Abraham  D. Determination of 3-methoxy-4-hydroxymandelic acid in urine. Clin Chem Acta  1962; 7: 285. [DOI] [PubMed] [Google Scholar]
  • 12. Pisano  JJ. In: Rall  JE, Kopin  IJ (eds), Methods in Investigative and Diagnostic Endocrinology, Vol I. American Elsevier, New York:  1972: 474. [Google Scholar]
  • 13. Baylin  SB. Medullary carcinoma of the thyroid gland: use of biochemical parameters in detection and surgical management of the tumour. Surg Clin North Am  1974; 54: 309. [DOI] [PubMed] [Google Scholar]
  • 14. Chong  GC, Beahrs  OH, Sizemore  GW, Woolner  LH. Medullary carcinoma of the thyroid gland. Cancer  1975; 35: 695. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Surgery are provided here courtesy of Oxford University Press

RESOURCES